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17 Abstract
18 The direct delivery of antibiotics to the lung has been considered an effective approach 
19 to treat pulmonary tuberculosis, which represents approximately 80% of total cases. In 
20 this sense, this work aimed at producing inhalable chitosan microparticles simultaneously 
21 associating isoniazid and rifabutin, for an application in pulmonary tuberculosis therapy. 
22 Spray-dried chitosan microparticles were obtained with adequate flow properties for deep 
23 lung delivery (aerodynamic diameter of 4 µm) and high drug association efficiencies 
24 (93% for isoniazid and 99% for rifabutin). The highest concentration of microparticles 
25 that was tested (1 mg/mL) decreased the viability of macrophage-differentiated THP-1 
26 cells to around 60% after 24 h exposure, although no deleterious effect was observed in 
27 human alveolar epithelial (A549) cells. The release of LDH was, however, increased in 
28 both cells. Chitosan microparticles further evidenced capacity to activate macrophage-
29 like cells, inducing cytokine secretion well above basal levels. Moreover, the propensity 
30 of macrophages to internalise microparticles was demonstrated, with uptake levels over 
31 90%. Chitosan microparticles also inhibited bacterial growth by 96%, demonstrating that 
32 the microencapsulation preserved drug antibacterial activity in vitro. Overall, the obtained 
33 data suggest the potential of chitosan microparticles systems for inhalable lung 
34 tuberculosis therapy.
35




40 Although tuberculosis (TB) is a curable condition, in 2016 it caused 1.3 million 
41 deaths worldwide [1]. As pulmonary TB represents approximately 80% of total cases, the 
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42 direct delivery of antibiotics to the infection site has been explored as an effective 
43 approach to treat the disease. However, the airway structure, local degradation and 
44 specific defence mechanisms (e,g. mucociliary clearance) are some limitations imposed 
45 by the pulmonary route [2]. Such limitations may be overcome by drug 
46 microencapsulation, a strategy that demands the design of inhalable carriers capable of 
47 reaching the alveoli, where infected macrophages reside. Additionally, further benefit 
48 may be attained if the carriers can be recognised by macrophage surface receptors. This 
49 can be mediated by the chemical composition of chitosan (CS), composed by N-
50 acetylglucosamine and D-glucosamine residues, the former already described to be 
51 recognised by macrophages [3], thus, possibly, potentiating phagocytosis. Other materials 
52 have been proposed to mediate the referred macrophage recognition and our group has 
53 recently published other works reporting the ability of fucoidan microparticles to provide 
54 this effect [4,5]. Nevertheless, CS is, in comparison, much more explored as matrix 
55 material, while the report of macrophage targeting ability of CS-based microparticles is 
56 scarce. In turn, CS microparticles were previously proposed as inhalable carriers of 
57 isoniazid [6], in a study focusing essentially on the chemical analysis of microparticles 
58 and their mucoadhesive capacity.
59 In this context, the present work aimed at producing inhalable CS microparticles 
60 (MP) that efficiently associate both isoniazid (INH) and rifabutin (RFB) in a single 
61 formulation for an application in pulmonary TB therapy. The proposed combined therapy 
62 is in agreement with WHO guidelines recommended for active pulmonary TB [1]. 
63 Microparticles were characterised and their respirability evaluated along with 
64 biocompatibility and antibacterial activity in vitro. Furthermore, the potential affinity of 
65 the produced carriers for alveolar macrophages was assessed, as well as their capacity to 
66 activate the target cells. 
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67 2. Materials and methods
68 2.1. Materials
69 CS (low molecular weight, 75-85% deacetylation degree, 116 kDa), buffer 
70 solution pH 5 (citric acid ~0.096 M, sodium hydroxide ~0.20 M), dimethylformamide 
71 (DMF), Dulbecco’s modified Eagle’s medium (DMEM), hydrogen chloride (HCl), 
72 isoniazid (INH,), lipopolysaccharide (LPS), N-(3- dimethylaminopropyl)-N´-
73 ethylcarbodiimide hydrochloride (EDAC), non-essential amino acids solution, 
74 penicillin/streptomycin (10000 units/mL, 10000 g/mL), sodium dodecyl sulphate (SDS), 
75 trypan blue solution (0.4%), trypsin-EDTA solution (2.5 g/L trypsin, 0.5 g/L EDTA), and 
76 triton-X 100 were purchased from Sigma-Aldrich (Germany). Lactate dehydrogenase 
77 (LDH) kit was supplied by Takara Bio (Tokyo, Japan), while RPMI 1640 and Ham’s F12 
78 media were provided by Lonza Group AG (Switzerland). Rifabutin (RFB) was obtained 
79 from Chemos (GmbH, Germany) and phorbol 12-myristate 13-acetate (PMA) by Cayman 
80 Chemicals (USA). Tween 80®, Phosphate buffer saline (PBS) tablets pH 7.4, and 
81 thiazolyl blue tetrazolium bromide (MTT) were purchased from Amresco (USA). 
82 Dimethyl sulfoxide (DMSO) was supplied by VWR (France) and fetal bovine serum 
83 (FBS) along with L-glutamine solution (200 mM) by Gibco (Life Technologies, USA). 
84 Middlebrook 7H9 (M7H9; 4.7 g/L) and OADC (oleic acid, albumin, dextrose and 
85 catalase) were obtained from Remel (Lenexa, USA). Quantikine® HS ELISA kits for 
86 TNF-α and IL-8 were from R&D Systems (USA). All other chemicals were reagent grade. 
87 Ultrapure water (MilliQ, Millipore, UK) was used throughout the studies. 
88
89 2.2 Microparticle production
90 Microparticles were obtained from CS (2% w/v, dissolved in 1% v/v acetic acid) 
91 solutions, containing both INH and RFB. INH was solubilised in 1% (v/v) acetic acid, 
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92 whereas RFB was dissolved in 10% (v/v) ethanol. Drugs were ground prior to 
93 solubilisation and afterwards incorporated dropwise into the CS solution. Drugs were 
94 added to obtain final CS/INH/RFB mass ratio of 10/1/0.5. A formulation of CS/INH/RFB 
95 = 10/1/0.2 (w/w) was specifically produced to be used in cytotoxicity assays (Section 
96 2.8). CS solutions (with and without drugs) were spray-dried, using a spray-dryer (Büchi 
97 B-290 Mini Spray Dryer, Switzerland) equipped with a high-performance cyclone, and 
98 operated as follows: spray flow rate of 473 L/h, aspirator at 80%, inlet temperature of 160 
99 ± 1 ºC and feed flow of 1.3 mL/min. The production yield was calculated as a percentage 
100 of the total solid content in the feed dispersion.
101 Fluorescent CS microparticles were also produced to be used in a single assay 
102 (macrophage capture – section 2.8). Briefly, CS (1% w/v, dissolved in 0.1 M acetic acid) 
103 reacted with fluorescein in the presence of EDAC [7]. After stirring (24 h, protected from 
104 light), the reaction mixture was dialysed against distilled water. The resulting solution 
105 was frozen, freeze-dried (FreeZone Benchtop Freeze Dry System, USA) and finally 
106 spray-dried, as described above, to produce unloaded fluorescent microparticles.
107
108 2.3. Surface morphology and particle size
109 The morphology of CS microparticles was observed with field emission scanning 
110 electron microscopy (FESEM Ultra Plus, Zeiss, Germany). To do so, samples were placed 
111 onto metal plates and sputter-coated (model Q150T S/E/ES, Quorum Technologies, UK) 
112 with iridium (5 nm thick).
113 The median volume diameter (D(v,0.5)) was determined using a SprayTec® 
114 (Malvern, UK), after dispersing microparticles (15 mg) in 2-propanol (15 mL) and 
115 sonicating (5 min). Analyses (n = 3) were performed with an obscuration threshold of 
116 10% [8]. 
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117 2.4. Drug association efficiency and loading capacity
118 Drug content was determined by dissolving dry powder (30 mg) in HCl 0.1 M (10 
119 mL), under constant stirring (20 min). Then, the solution was filtered (cellulose acetate, 
120 0.45 µm) before quantification by UV-Vis spectrophotometry (Pharmaspec UV-1700, 
121 Shimadazu, Japan) at 268.5 nm (INH) and 500 nm (RFB). The measurement at 500 nm 
122 provided a direct calculation of the RFB amount present in CS microparticles. In turn, the 
123 measurement performed at 268.5 nm required a 1:10 dilution and represented the sum of 
124 amounts of INH and RFB. The amount of INH was thus calculated by subtracting the 
125 amount of RFB from this value. Calibration curves were obtained from standard solutions 
126 of both drugs prepared using the medium resulting from dissolution of unloaded 
127 microparticles in HCl 0.1M. Drug association efficiency (AE) and microparticle loading 
128 capacity (LC) were estimated (n = 3) as follows [6]:
129
AE (%) = (Real amount of drug /Theoretical drug content) x 100 (1)
LC (%) = (Real drug content /Weight of microparticles) x 100 (2)
130
131 2.5. In vitro aerosolisation 
132 The aerodynamic assessment was determined as previously described in the 
133 literature [9], using the Andersen cascade impactor (ACI, Copley Scientific Ltd., UK) at 
134 a flow rate of 60 L/min. Cut-offs of the stages from −1 to 6 are the following: 8.60, 6.50, 
135 4.40, 3.20, 1.90, 1.20, 0.55 and 0.26 µm. For each determination (n = 3), three capsules 
136 (HPMC size 3; Quali-V-I, Qualicaps, Spain) were manually filled with microparticles (30 
137 mg/capsule) and aerosolised using the RS01 dry powder inhaler (Plastiape Spa, Italy). 
138 Aerosolised microparticles were rinsed with a mixture of water/acetonitrile (50/50, v/v), 
139 then sonicated (5 min), and filtered (0.45 µm, RC, Sartorius, USA). Drug deposition on 
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140 each stage of the ACI was determined by HPLC (Agilent 1200 series, Germany) at 275 
141 nm (diode array detector). The mobile phase was phosphate buffer 20 mM pH = 7 (A) 
142 and acetonitrile (B). The gradient started with 95:5 (A:B) during 5 min, reaching a ratio 
143 of 30:70 (A:B), in the following 3 min, a condition kept for 19 min. The injection volume 
144 was 20 µL and the flow rate was set at 1 mL/min. Drug deposition on each stage was 
145 determined from standard calibration curves.
146
147 2.6. Drug release 
148 In vitro drug release was conducted in citrate buffer pH 5 and PBS pH 7.4, both 
149 containing 1% (v/v) Tween® 80. To do so, dry powder (15 mg) was suspended in the 
150 release medium (10 mL) and maintained under mild shaking (100 rpm; Orbital Shaker 
151 OS 10, Biosan, Latvia) at 37 ºC (Dry line; VWR, USA). Samples of 1 mL were taken at 
152 pre-established time intervals, centrifuged (16,000 x g, 15 min; Heraeus Fresco 17 
153 Centrifuge, ThermoScientific, USA) and then filtered (0.45 µm). Drug quantification was 
154 performed by spectrophotometry as described above (section 2.5). Calibration curves 
155 were established using standard solutions of drugs dissolved in the medium resulting from 
156 the incubation of unloaded CS microparticles with the release medium, followed by 
157 centrifugation (4000 rpm, 20 min; Centrifuge MPW 223e, Poland) and filtration (0.45 
158 µm). 
159
160 2.7. Evaluation of cytotoxicity 
161 The cytotoxic profile of microparticles was evaluated by the MTT assays and the 
162 LDH release assay. A549 cells (American Type Culture Collection, UK) and THP-1 
163 human monocytic cells (Leibniz-Institut DSMZ, Germany) were used, the latter 
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164 undergoing a pre-treatment with PMA (50 nM, 48 h exposure) for differentiation into 
165 macrophage phenotype [10]. 
166 To perform the assays, A549 cells (1.0 x 104 cells/well) and macrophage-
167 differentiated THP-1 cells (3.5 x 105 cells/well) were exposed (3 h and 24 h) to unloaded 
168 and drug-loaded CS microparticles at concentrations of 0.1, 0.5 and 1.0 mg/mL. Dry 
169 powders were dispersed in the proper cell culture medium (CCM) without FBS. Free 
170 drugs were tested as control at concentrations equivalent to their theoretical loadings in 
171 microparticles: 0.01, 0.05 and 0.1 mg/mL (INH) and 0.005, 0.025 and 0.05 mg/mL (RFB). 
172 SDS (solution at 2%, w/v) was used as negative control of cell viability. The viability of 
173 treated cells was expressed as a percentage of that observed for the positive control 
174 (untreated cells). 
175 In simultaneous assays, the amount of LDH released by the cells upon contact 
176 with the microparticles (1 mg/mL) and controls was measured upon 24 h. Cell supernatant 
177 was collected, centrifuged and analysed using a commercial kit. LDH was quantified by 
178 spectrophotometry at 490 nm (Infinite M200, Tecan, Austria), with background 
179 correction at 690 nm. CCM was used as negative control and Triton-X100 as positive 
180 control (100% LDH release). LDH released upon incubation with each sample was 
181 determined by comparison with the positive control. The assay was performed in 
182 triplicate.
183
184 2.8. Interaction of CS microparticles with macrophages 
185 The ability of macrophage-like cells to internalise CS microparticles was 
186 evaluated by flow cytometry (FacScalibur cell analyser, BD Biosciences, Belgium). 
187 Macrophage-differentiated THP-1 (3.50 x 105 cells/mL) and rat alveolar macrophages 
188 NR8383 cells (2.0 x 105 cells/mL) were used for the assay, being exposed to fluorescent 
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189 CS microparticles at 50 and 200 µg/cm2. Microparticles were aerosolised using a Dry 
190 Powder Insufflator™ (Model DP-4, Penn-Century™, USA) and cell samples prepared as 
191 described elsewhere [7].  Untreated cells were considered the negative control. For each 
192 dose, experiments were performed at least three times (n ≥ 3).
193 Macrophage-differentiated THP-1 cells (3.5 x 105 cells/well) were further 
194 incubated (24 h) with drug-loaded CS microparticles and CS polymer (raw material) to 
195 evaluate the induction of TNF-α and IL-8 secretion. Cell supernatants (100 µL) were 
196 centrifuged (16,000 xg, 5 min) and the cytokines quantified using ELISA kits. 
197 Absorbance was detected at 450 nm with background correction at 540 nm. Values were 
198 expressed according to reference standard curves. The level of cytokines obtained from 
199 LPS- and CCM-treated cells were used as control. 
200
201 2.9. In vitro antibacterial effect
202 The susceptibility of Mycobacterium bovis BCG (DSM 43990; a gift from 
203 Universidade Nova de Lisboa – CEDOC/FCM-UNL) was evaluated in vitro. The 
204 minimum concentration of drug-loaded CS microparticles required to inhibit 
205 mycobacteria growth by 95–100% was determined by the MTT assay, according to a 
206 previously described protocol [5]. 
207 Assays were conducted after bacterial suspensions achieved an optical density 
208 value (OD600nm) of approximately 0.2, as measured by spectrophotometry (Infinite M200, 
209 Tecan, Austria). Bacterial suspensions (20 µL, n = 3) were inoculated with test samples 
210 serially diluted (180 µL). Bacterial suspension inoculated with broth in the absence of 
211 test samples were assumed as positive control, whereas M7H9 medium only (200 µL) 
212 was considered as negative control. Free drugs were also tested as control. After 1-week 
213 incubation (37 °C, Binder, USA), MTT (30 μL) sterile solution was added, following 1 h 
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214 incubation before the addition of DMSO (50 μL). Measurements (n = 3) were conducted 
215 by spectrophotometry at 540 nm. 
216
217 2.10. Statistical analysis
218 Sigmaplot (version 12.5) was used to statistically analyse the generated data. 
219 Student t-test and one-way analysis of variance (ANOVA) with the pairwise multiple 
220 comparison procedures (Holm-Sidak method) were performed. Differences were 
221 considered significant when p-values were smaller than 0.05. 
222
223 3. Results and Discussion
224 3.1. Production and characterisation of chitosan microparticles
225 Spray-drying yielded 75 ± 5% of dry powder, which is satisfactory and actually 
226 higher than other values recently report d for spray-dried CS microparticles [6,11]. In 
227 this case, high yields could be mainly attributed to the instrumentation design, since the 
228 use of high performance cyclone, instead of the manufacturer’s standard separator, 
229 greatly improved the powder yield [12]. The simultaneous association of INH and RFB 
230 to CS microparticles was effective, complying with the combined therapeutic regimen of 
231 TB, recommended by WHO [1]. Microparticles presented high and similar association 
232 efficiencies – INH (93 ± 4%) and RFB (99 ± 5%) –  despite the different aqueous 
233 solubilities: 125 mg/mL for INH [7] and 0.19 mg/mL for RFB [13]. Loading capacity of 
234 both antibiotics was found to be 8.1 ± 0.3% (INH) and 4.3 ± 0.2% (RFB), values close to 
235 the theoretical maximum (8.7% for INH and 4.4% for RFB). In this work, INH was 
236 included in higher amount than RFB, as the latter is a more potent antibiotic [14], and 
237 also has a more toxic profile, as demonstrated later (section 3.4). Moreover, the amount 
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238 of CS in microparticles was maintained purposely high in order to favour macrophage 
239 internalisation [3].
240 These results demonstrate the great capacity of spray-drying to provide drug 
241 association, similarly to what was reported for other CS-based microparticles associating 
242 antitubercular drugs. However, unlike the present study, the production of the referred 
243 microparticles required more than one production step and involved the use of a 
244 crosslinking agent (e.g. tripolyphosphate) in order to improve drug retention in the 
245 formulation [6]. The literature reports the production of CS microparticles loaded with 
246 one [6,15] or more antitubercular drugs [16], using spray-drying or other methods. 
247 Nevertheless, such studies included dispersing agents (e.g. lactose) and/or other 
248 polysaccharides (e.g. alginate) in the process. To the best of our knowledge, this is the 
249 first report describing single step produced spray-dried CS microparticles, combining 
250 INH and RFB in a single formulation. 
251 The morphological analysis showed that CS microparticles are spherical, with 
252 wrinkled surfaces that generally become smoother after drug incorporation (Figure 1). 
253 These morphologies are coincident with previous descriptions of spray-dried CS 
254 microparticles [17]. The median volume diameter (D(v,0.5)) was determined as 5.9 ± 1.7 
255 µm for drug-loaded microparticles, which agrees with Figure 1.
256
257 Insert [Figure 1 near here]
258
259 The aerosolisation properties of CS microparticles were investigated in vitro using 
260 an ACI and the obtained data are displayed in Table 1. The assessment revealed high 
261 emitted doses (80–90%) with respirable fractions (FPF ≤ 5µm) of approximately 45%, 
262 indicating adequate flowability of microparticles, and supporting the intended 
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263 application. Moreover, drug recoveries were found to be 91 ± 4% (INH) and 87 ± 1% 
264 (RFB), complying with the recommendations of the European Pharmacopeia [9]. 
265
266 Insert [Table 1 near here]
267
268 The formulation generated adequate aerosol size (MMAD around 4 µm) for 
269 efficient lung deposition, as particles with aerodynamic diameter of 1-5 μm have great 
270 tendency to reach the respiratory zone, while those with less than 2 µm are prone to 
271 deposit in peripheral airways [18]. Therefore, drug-loaded CS microparticles display 
272 suitable aerodynamic diameter to reach the respiratory zone and possibly to be 
273 internalised by macrophages, the target cells, which are described to uptake particulate 
274 material with diameter within 1–6 µm [19]. 
275 Drug deposition profiles evidenced co-deposition of both INH and RFB on the 
276 different ACI stages (Figure 2). This observation reinforces that spray-drying was 
277 adequate to associate two antibiotics in a single dry powder formulation for an application 
278 in TB therapy, as the drugs are evenly distributed. In summary, the proposed systems 
279 exhibited acceptable aerodynamic properties for deep lung delivery of anti-TB drugs.
280
281 Insert [Figure 2 near here]
282
283 3.2. Drug release profiles
284 Drug release profiles were determined in PBS pH 7.4, containing 1% (v/v) Tween 
285 80®, which mimics the natural surfactant existent in the lung lining fluid [20], and also 
286 facilitates RFB dissolution in the medium, considering its poor water solubility. The 
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287 release of drugs was further assessed in a medium of pH 5 that simulates the intracellular 
288 environment of alveolar macrophages [21]. 
289 Figure 3 shows the release of INH and RFB from CS microparticles. The two 
290 antibiotics evidenced complete release within two hours (Figure 3 a,b). At pH 7.4 and at 
291 initial time points, the release of RFB was slower compared to INH (Figure 3 a, p <0.05). 
292 At these time points, the amount of RFB was below the limit of detection, justifying 
293 plotting only from 30 min on, time at which about 70% of RFB was released. On the other 
294 hand, INH released almost completely (over 90%) in the same period and RFB reached 
295 approximately 100% release at 120 min. However, in acidic medium, no significant 
296 difference was perceived between INH and RFB profiles at any time point (Figure 3 b). 
297 Although not statistically significant, RFB showed faster release at pH 5 (97% at 60 min) 
298 than at pH 7.4 (87% at 60 min), certainly due to its higher solubility in acidic medium. 
299 Overall, drug release profiles exhibited similar patterns in both media, suggesting that pH 
300 does not have a significant impact on drug release from CS microparticles. 
301
302 Insert [Figure 3 near here]
303
304 The release of both drugs under both conditions was similar to that reported for 
305 other polysaccharide microparticles loaded with either INH [23] or RFB proposed for 
306 pulmonary delivery [24]. Although not immediate, the release may be considered rapid, 
307 as in all cases over 70% of the drug was released in the first 30 min. Nevertheless, it must 
308 be considered that the used in vitro setting does not represent accurately the lung 
309 physiology. In fact, the amount of liquid is overestimated in the assay, as microparticles 
310 are immersed in the release media, not simulating the volume and thickness of alveolar 
311 lung lining fluid [25]. In this way, the rapid release of the drugs, which follows 
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312 microparticle dissolution, is certainly different from in vivo environment, wherein 
313 microparticles would be only partially in contact with the alveolar fluid. Thus, in vivo 
314 profiles will probably show slower release of drugs [25,26]. 
315
316 3.3. Evaluation of cytotoxicity 
317 The effect of unloaded and drug-loaded CS microparticles on cell viability was 
318 evaluated in A549 cells and macrophage-differentiated cells by the MTT assay. For the 
319 purpose of discussion, the occurrence of a cytotoxic effect was assumed when the material 
320 decreased cell viability below 70% [27].
321 The exposure of A549 cells to drug-loaded CS microparticles revealed cell 
322 viability over 70% at all tested concentrations and at both time points (3 h and 24 h), as 
323 depicted in Figure 4 a,b. These results indicate absence of cytotoxicity of the formulation. 
324 However, despite no significant differences were observed in terms of dose, the viability 
325 of A549 cells decreased over time, suggesting a time-dependent effect (p<0.05). In turn, 
326 a dose-dependent effect was perceived on macrophage-differentiated THP-1 cells, as cell 
327 viability decreased from 90% (0.1 mg/mL) to 59% at the highest tested dose (1.0 mg/mL) 
328 upon 24 h exposure (p<0.05, Figure 4 b). The observed toxic effect of microparticles on 
329 these cells is possibly related with RFB content, an antibiotic that has also shown to be 
330 toxic in vivo [28]. Overall, both cell lines tolerated well the exposure to unloaded CS 
331 microparticles (Figure 4 a,b), which is in agreement with other studies showing low 
332 toxicity of CS-based systems tested in the same cell lines [29,30]. The effect of the free 
333 drugs, in the concentrations corresponding to those loaded in the microparticles, was 
334 reported in a previous work [5]. Free INH showed mild effect on the viability of both cell 
335 lines, remaining above 76% in all tested conditions. Oppositely, free RFB (0.05 mg/mL, 
336 the highest concentration tested) induced around 50% cell viability in the two cell lines. 
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337 A concentration-dependent effect of RFB on cell viability was confirmed in the present 
338 work by testing microparticles with lower RFB content (CS/INH/RFB = 10/1/0.2, w/w), 
339 which were purposely produced to undergo this assay. The decrease in RFB loading led 
340 to viability of macrophage-like cells above 70% in all tested conditions referred above 
341 (data not shown). Interestingly, free RFB at 0.025 mg/mL had demonstrated  a cytotoxic 
342 effect 24 h-post exposure to macrophage-differentiated THP-1 cells [5], but the 
343 detrimental effect was not perceived for drug-loaded CS microparticles at the same time 
344 point (Figure 4 b). Therefore, it is suggested that microencapsulation may revert RFB 
345 cytotoxic effect at some extent (p<0.05), as proposed previously [5]. 
346 Insert [Figure 4 near here]
347
348 It must be mentioned that the highest dose tested in the present study is considered 
349 much higher than that to be observed in vivo upon inhalation, taking into account the large 
350 area of the alveolar zone [31]. Therefore, in vivo concentrations will most likely correlate 
351 those of the lower doses tested, at which no cytotoxicity were perceived. In this sense, 
352 both cell lines were considered to tolerate well the exposure to CS/INH/RFB 
353 microparticles.
354 Complementarily to the determination of cell viability through metabolic activity, 
355 the cell membrane integrity was assessed by determining the level of LDH released from 
356 both cell lines upon exposure to the microparticles and free drugs. 
357 The incubation with CCM resulted in basal release of LDH of 21% and 34%, for 
358 A549 and macrophage-differentiated THP-1 cells, respectively (Figure 5). Unloaded CS 
359 microparticles did not raise the release of the enzyme, evidencing that CS itself did not 
360 show toxic effect on any cell line (Figure 5), as also reported elsewhere [32,33]. 
361
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362 Insert [Figure 5 near here]
363
364 Drug-loaded microparticles exhibited toxicity on macrophage-differentiated 
365 THP-1 cells, with 49% LDH release, which is higher than the 34% of CCM (p<0.05). 
366 Unexpectedly, A549 cells also showed significantly increased release of LDH (28%) 
367 upon exposure to drug-loaded microparticles, compared with CCM (p<0.05, Figure 5). 
368 This slight cytotoxicity was not evident in the MTT assay (cell viability around 80%). 
369 Despite the increased release of LDH observed in both cell lines, the developed carriers 
370 induced lower LDH release than free RFB (p<0.05) and an effect similar to that of free 
371 INH, thus suggesting the ability of microencapsulation to potentially reduce drug 
372 toxicological effects. Data regarding the exposure of both cell lines to free drugs were 
373 presented in a previous publication [5]. Importantly, the level of enzyme secreted after 
374 exposure to microparticles is far lower than the observed for the positive control.
375 The different outcomes registered in both assays (MTT and LDH release) have 
376 been reported [34] and are due to the fact that the two methods assess cell-particle 
377 interactions in different ways. Microparticles possibly interact with cytoplasmic 
378 membrane, promoting cell lysis, but not necessarily interfere with intracellular functions, 
379 such as mitochondrial dehydrogenase activity [35]. Contrarily, particles may enhance 
380 metabolic activity, despite the small number of viable cells, leading to an overestimation 
381 of cell viability, determined by MTT assay [36]. Therefore, the measurement of LDH 
382 release should be taken as a complement to the MTT assay, but there is the need to extend 
383 the range of tests to rigorously characterise the safety profile of the proposed carriers.
384
385 3.4. Interaction of microparticles with macrophages
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386 Considering the intended application of the produced carriers, both the phagocytosis 
387 of microparticles and the subsequent induction of macrophage activation would be 
388 beneficial. The preliminary internalisation of CS microparticles was assessed in 
389 macrophage-differentiated THP-1 cells and rat alveolar macrophages NR8383. Cells 
390 were exposed to fluorescently-labelled CS microparticles for 2 h, since 50 – 75% of 
391 microparticles are reported to be phagocytosed within 2–3 h [37]. Microparticle uptake 
392 by differentiated THP-1 cells was very high at both concentrations (94.3 ± 1.5 for 50 
393 µg/cm2 and 98.1 ± 1.8% for 200 µg/cm2), as depicted in Figure 6. Likewise, NR8383 cells 
394 internalised up to 99.9 ± 0.1, regardless of the dose. These preliminary results suggest 
395 high affinity of macrophages for CS microparticles independently of concentrations and 
396 cell type. It is well-known that macrophages are specialised cells, which recognise and 
397 engulf particulate matter, and thus the internalisation of particles was expected. 
398 Nevertheless, residues of N-acetylglucosamine, a structural unit of CS, have been 
399 described to be preferentially recognised by macrophages [3]. The presence of such units 
400 possibly mediated the phagocytic mechanism, which could explain the high affinity of 
401 cells for the produced microparticles. However, it is deemed adequate to consider future 
402 assays providing comparison with a material devoid of units recognised by macrophages. 
403 In this way, the favourable recognition of CS-based carriers by macrophage-like cells 
404 could be unequivocally established. Furthermore, complementation with confocal 
405 microscopy would strenghten the data.
406
407 Insert [Figure 6 near here]
408
409 Following phagocytosis, macrophages may become activated, which contributes to 
410 the efficient control of the proliferation and dissemination of pathogens by producing 
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411 cytokines (e.g. TNF-α and IL-8) [38]. Such pro-inflammatory cytokines are reported to 
412 be secreted by human alveolar macrophages upon infection with M. tuberculosis [39]. In 
413 light of this, macrophage-differentiated THP-1 cells were exposed (24 h) to CS/INH/RFB 
414 microparticles and the levels of TNF-α and IL-8 were quantitatively determined in cell 
415 culture supernatants. CCM and lipopolysaccharide (LPS) were used as negative and 
416 positive controls, respectively [5]. 
417 Drug-loaded microparticles induced the secretion of a considerable amount of 
418 cytokines,  614  pg/mL for TNF-α and 10.6 x 103 pg/mL for IL-8 (Figure 7 a,b). In both 
419 cases the values were much higher compared with basal secretion of cells incubated with 
420 CCM (p<0.05). No significant differences were found between TNF-α secretion 
421 promoted by loaded carriers and CS polymer (Figure 7 a), but a significant difference was 
422 observed for IL-8 (Figure 7 b; p<0.05). In that case, drug association apparently interfered 
423 with cell receptor signaling during immune activation, thus decreasing macrophage 
424 activation ability. A possible explanation for this effect is that the lenght of the released 
425 polymeric chain and also the number of fractions of N-acetylglucosamine residues 
426 influence the level of immune activation, and drug association can possibly alter this 
427 pattern [40]. As referred previously, N-acetylglucosamine moieties have reported 
428 recognition by macrophage receptors [3], thus, possibly, inducing cell activation.
429 Although the formulation induced cytokine production at lower levels compared to 
430 LPS, the exposure of macrophage-like cells to CS microparticles resulted in the increased 
431 release of TNF-α and IL-8 in relation to CCM (p<0.05). Other studies describe similar 
432 effects [6,41]. Although the natural immunomodulatory properties of CS have been 
433 already demonstrated [42], the mechanism through which CS particles induce immune 
434 response still needs to be unveiled.
435
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436 Insert [Figure 7 near here]
437
438 3.5. In vitro antibacterial effect 
439 The viability of M. bovis DSM 43990 cells was verified upon exposure to drug-
440 loaded CS microparticles and free drugs (either alone or in combination). MIC values 
441 were calculated in relation to control (culture of mycobacteria), assumed as 100% 
442 bacterial growth. MIC value of free INH was 0.125 µg/mL, being alligned with literature 
443 descriptions [43]. RFB had a much lower MIC value (0.004 µg/mL), evidencing its higher 
444 antimicrobial effect compared to INH. This is possibily related to RFB lipophilicity, 
445 which may facilitate cell membrane permeation [44]. Different MIC values of RFB have 
446 been reported, varying according to the methodologies used to test suceptibility and the 
447 tested strains of M. bovis [43].
448 In combination, free INH and RFB inhibited bacterial growth by 94 ± 1%, 
449 presenting MIC values of 0.008 µg/mL and 0.004 µg/mL, respectively. Curiously, the 
450 MIC of INH alone (0.125 µg/mL) decreased in the presence of RFB, which MIC remained 
451 unchanged. This different behaviour between INH and other antibiotics has been 
452 described [45] and the stronger antibacterial acitivity of RFB compared to INH is also 
453 reported [14]. Additionally, a dose of 0.08 µg/mL of drug-loaded CS microparticles was 
454 the minimum concentration needed to inhibit mycobacterial growth by 96 ± 1%. At this 
455 concentration, microparticle drug contents are approximately 0.007 µg/mL (INH) and 
456 0.004 µg/mL (RFB), considering the association efficiencies. It is worth noting that these 
457 results are in line with MIC values determined for the combined solution of free 
458 antibiotics. In other words, no differences were perceived in terms of inhibition effects 
459 comparing drug-loaded CS microparticles (96 ± 1%) and free INH/RFB (94 ± 1%). This 
460 indicates that the combined microencapsulation of the drugs did not intefere with their 
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461 antibacterial activity. As well, results demonstrate that the proposed formulation can 
462 potentially inhibit the growth of M. bovis in vitro.
463 Conclusion 
464 Inhalable CS dry powder loaded with both INH and RFB was prepared by spray-
465 drying, with drug association efficiencies of 93% (INH) and 99% (RFB). The developed 
466 microparticles displayed MMAD around 4 µm and FPF of approximately 45%, thus 
467 showing suitable aerodynamic properties for deep lung delivery. Cytotoxicity assays 
468 demonstrated that the formulation is well tolerated by alveolar epithelial cells. 
469 Nevertheless, a slight decrease on cell viability of macrophage-like cells (to 60%) was 
470 observed at the highest microparticle concentration tested (1.0 mg/mL) after 24 h 
471 exposure, although this dose is possibly overestimated comparing to real in vivo 
472 conditions. Furthermore, a preliminary evaluation indicated strong ability of CS 
473 microparticles to undergo macrophage uptake (up to 99.9%) and the ability to induce 
474 macrophage activation. Additionally, drug antibacterial activity against M. bovis was 
475 demonstrated to be preserved after drug microencapsulation. In conclusion, the developed 
476 dual drug-loaded CS microparticles demonstrated to be potential candidates for inhalable 
477 therapy of pulmonary TB. Despite that, long-term effects of CS microparticles upon 
478 pulmonary administration in vivo, along with in vivo antibacterial efficacy of the systems, 
479 are very relevant evaluations to perform in the future.
480
481 Declaration of interest statement
482 The authors declare no conflict of interest.
483
484 Acknowledgements
Page 20 of 37
URL: http:/mc.manuscriptcentral.com/lddi  Email:hugh.smyth@austin.utexas.edu





























































For Peer Review Only
21
485 Funding from the Portuguese Foundation for Science and Technology (PTDC/DTP-
486 FTO/0094/2012, UID/Multi/04326/2013 and UID/BIM/04773/2013) is acknowledged. 
487 Ludmylla Cunha acknowledges PhD grant (BEX 1168/13-4) supported by CAPES – 
488 Brazil.
489 References
490 1. World Health Organization Global Tuberculosis Report 2017. World Health 
491 Organization, Geneva.; Geneva, Switzerland, 2017;
492 2. Liang, Z.; Ni, R.; Zhou, J.; Mao, S. Recent advances in controlled pulmonary 
493 drug delivery. Drug Discov. Today 2015, 20, 380–389, 
494 doi:10.1016/j.drudis.2014.09.020.
495 3. East, L.; Isacke, C. M. The mannose receptor family. Biochim. Biophys. Acta - 
496 Gen. Subj. 2002, 1572, 364–386.
497 4. Cunha, L.; Rosa da Costa, A. M.; Lourenço, J. P.; Buttini, F.; Grenha, A. Spray-
498 dried fucoidan microparticles for pulmonary delivery of antitubercular drugs. J. 
499 Microencapsul. 2018, 35, 392–405, doi:10.1080/02652048.2018.1513089.
500 5. Cunha, L.; Rodrigues, S.; Buttini, F.; Grenha, A. Inhalable fucoidan 
501 microparticles combining two antitubercular drugs with potential application in 
502 pulmonary tuberculosis therapy. Polymers (Basel). 2018, 10, 1–19, 
503 doi:10.3390/polym10060636.
504 6. Oliveira, P. M.; Matos, B. N.; Pereira, P. A. T.; Gratieri, T.; Faccioli, L. H.; 
505 Cunha-Filho, M. S. S.; Gelfuso, G. M. Microparticles prepared with 50–190 kDa 
506 chitosan as promising non-toxic carriers for pulmonary delivery of isoniazid. 
507 Carbohydr. Polym. 2017, 174, 421–431, doi:10.1016/J.CARBPOL.2017.06.090.
508 7. Alves, A.; Cavaco, J.; Guerreiro, F.; Lourenço, J.; Rosa da Costa, A.; Grenha, A. 
509 Inhalable antitubercular therapy mediated by locust bean gum microparticles. 
Page 21 of 37
URL: http:/mc.manuscriptcentral.com/lddi  Email:hugh.smyth@austin.utexas.edu





























































For Peer Review Only
22
510 Molecules 2016, 21, 1–22, doi:10.3390/molecules21060702.
511 8. Martinelli, F.; Balducci, A. G.; Kumar, A.; Sonvico, F.; Forbes, B.; Bettini, R.; 
512 Buttini, F. Engineered sodium hyaluronate respirable dry powders for pulmonary 
513 drug delivery. Int. J. Pharm. 2017, 517, 286–295, 
514 doi:10.1016/j.ijpharm.2016.12.002.
515 9. Buttini, F.; Colombo, G.; Kwok, P. C. L.; Wui, W. T. Aerodynamic assessment 
516 for inhalation products: Fundamentals and current pharmacopoeial methods. In 
517 Inhalation drug delivery: Techniques and products; Colombo, P. Traini, D. and 
518 Buttini, F., Ed.; Wiley-Blackwell: West Sussex, United Kingdom, 2013; pp. 91–
519 119.
520 10. Lund, M. E.; To, J.; O’Brien, B. A.; Donnelly, S. The choice of phorbol 12-
521 myristate 13-acetate differentiation protocol influences the response of THP-1 
522 macrophages to a pro-inflammatory stimulus. J. Immunol. Methods 2016, 430, 
523 64–70, doi:10.1016/j.jim.2016.01.012.
524 11. Pai, R. V.; Jain, R. R.; Bannalikar, A. S.; Menon, M. D. Development and 
525 evaluation of chitosan microparticles based dry powder inhalation formulations 
526 of rifampicin and rifabutin. J. Aerosol Med. Pulm. Drug Deliv. 2015, 28, 1–17, 
527 doi:10.1089/jamp.2014.1187.
528 12. Maury, M.; Murphy, K.; Kumar, S.; Shi, L.; Lee, G. Effects of process variables 
529 on the powder yield of spray-dried trehalose on a laboratory spray-dryer. Eur. J. 
530 Pharm. Biopharm. 2005, 59, 565–573.
531 13. Anshakova, A. V; Yu Konyukhov, V. Study by inverse gas chromatography of 
532 the solubility of rifabutin in water in the presence of cyclodextrin. Russ. J. Appl. 
533 Chem. 2017, 90, 209–213, doi:10.1134/S1070427217020082.
534 14. Jabes, D.; Della Bruna, C.; Rossi, R.; Olliaro, P. Effectiveness of rifabutin alone 
Page 22 of 37
URL: http:/mc.manuscriptcentral.com/lddi  Email:hugh.smyth@austin.utexas.edu





























































For Peer Review Only
23
535 or in combination with isoniazid in preventive therapy of mouse tuberculosis. 
536 Antimicrob. Agents Chemother. 1994, 38, 2346–2350, 
537 doi:10.1128/AAC.38.10.2346.
538 15. Lacerda, L.; Parize, A. L.; Fávere, V.; Laranjeira, M. C. M.; Stulzer, H. K. 
539 Development and evaluation of pH-sensitive sodium alginate/chitosan 
540 microparticles containing the antituberculosis drug rifampicin. Mater. Sci. Eng. C 
541 2014, 39, 161–167, doi:10.1016/J.MSEC.2014.01.054.
542 16. Pandey, R.; Khuller, G. K. Chemotherapeutic potential of alginate-chitosan 
543 microspheres as anti-tubercular drug carriers. J. Antimicrob. Chemother. 2004, 
544 53, 635–640, doi:10.1093/jac/dkh139.
545 17. Corrigan, D. O.; Healy, A. M.; Corrigan, O. I. Preparation and release of 
546 salbutamol from chitosan and chitosan co-spray dried compacts and 
547 multiparticulates. Eur. J. Pharm. Biopharm. 2006, 62, 295–305.
548 18. Buttini, F.; Brambilla, G.; Copelli, D.; Sisti, V.; Balducci, A. G.; Bettini, R.; 
549 Pasquali, I. Effect of flow rate on in vitro aerodynamic performance of 
550 NEXThaler ® in comparison with Diskus ® and Turbohaler ® Dry Powder 
551 Inhalers. J. Aerosol Med. Pulm. Drug Deliv. 2016, 29, 167–178, 
552 doi:10.1089/jamp.2015.
553 19. Hirota, K.; Hasegawa, T.; Hinata, H.; Ito, F.; Inagawa, H.; Kochi, C.; Soma, G. 
554 I.; Makino, K.; Terada, H. Optimum conditions for efficient phagocytosis of 
555 rifampicin-loaded PLGA microspheres by alveolar macrophages. J. Control. 
556 Release 2007, 119, 69–76, doi:10.1016/j.jconrel.2007.01.013.
557 20. Eleftheriadis, G. K.; Akrivou, M.; Bouropoulos, N.; Tsibouklis, J.; Vizirianakis, 
558 I. S.; Fatouros, D. G. Polymer−lipid microparticles for pulmonary delivery. 
559 Langmuir 2018, 34, 3438–3448, doi:10.1021/acs.langmuir.7b03645.
Page 23 of 37
URL: http:/mc.manuscriptcentral.com/lddi  Email:hugh.smyth@austin.utexas.edu





























































For Peer Review Only
24
560 21. Vieira, A. C.; Magalhães, J.; Rocha, S.; Cardoso, M. S.; Santos, S. G.; Borges, 
561 M.; Pinheiro, M.; Reis, S. Targeted macrophages delivery of rifampicin-loaded 
562 lipid nanoparticles to improve tuberculosis treatment. Nanomedicine 2017, 12, 
563 2721–2736, doi:10.2217/nnm-2017-0248.
564 22. Chauhan, D.; Patel, A.; Shah, S. Influence of selected natural polymers on in-
565 vitro release of colon targeted Mebeverine HCl matrix tablet. Int. J. Drug Dev. 
566 Res. 2012, 4, 247–255.
567 23. Kundawala, A. J.; Patel, V. a; Patel, H. V; Choudhary, D. Influence of 
568 formulation components on aerosolization properties of isoniazid loaded chitosan 
569 microspheres. Intenational J. Pharm. Sci. Drug Res. 2011, 3, 297–302.
570 24. Upadhyay, T. K.; Fatima, N.; Sharma, D.; Saravanakumar, V.; Sharma, R. 
571 Preparation and characterization of beta-glucan particles containing a payload of 
572 nanoembedded rifabutin for enhanced targeted delivery to macrophages. EXCLI 
573 J. 2017, 16, 210–228, doi:10.17179/excli2016-804.
574 25. Haghi, M.; Ong, H. X.; Traini, D.; Young, P. Across the pulmonary epithelial 
575 barrier: Integration of physicochemical properties and human cell models to 
576 study pulmonary drug formulations. Pharmacol. Ther. 2014, 144, 235–252, 
577 doi:10.1016/J.PHARMTHERA.2014.05.003.
578 26. Bur, M.; Huwer, H.; Muys, L.; Lehr, C.-M. Drug transport across pulmonary 
579 epithelial cell monolayers: Effects of particle size, apical liquid volume, and 
580 deposition technique. J. Aerosol Med. Pulm. Drug Deliv. 2010, 23, 119–127, 
581 doi:10.1089/jamp.2009.0757.
582 27. ISO 10993-5 Biological Evaluation of Medical Devices Part 5: Tests for In Vitro 
583 Cytotoxicity. International Organization for Standardization.; Geneva, 
584 Switzerland, 2009;
Page 24 of 37
URL: http:/mc.manuscriptcentral.com/lddi  Email:hugh.smyth@austin.utexas.edu





























































For Peer Review Only
25
585 28. Barluenga, J.; Aznar, F.; García, A. B.; Cabal, M. P.; Palacios, J. J.; Menéndez, 
586 M. A. New rifabutin analogs: Synthesis and biological activity against 
587 Mycobacterium tuberculosis. Bioorganic Med. Chem. Lett. 2006, 16, 5717–5722, 
588 doi:10.1016/j.bmcl.2006.08.090.
589 29. Abbas, Y.; Azzazy, H. M. E.; Tammam, S.; Lamprecht, A.; Ali, M. E.; Schmidt, 
590 A.; Sollazzo, S.; Mathur, S. Development of an inhalable, stimuli-responsive 
591 particulate system for delivery to deep lung tissue. Colloids Surfaces B 
592 Biointerfaces 2016, 146, 19–30, doi:10.1016/J.COLSURFB.2016.05.031.
593 30. Boyles, M. S. P.; Kristl, T.; Andosch, A.; Zimmermann, M.; Tran, N.; Casals, E.; 
594 Himly, M.; Puntes, V.; Huber, C. G.; Lütz‑meindl, U.; Duschl, A. Chitosan 
595 functionalisation of gold nanoparticles encourages particle uptake and induces 
596 cytotoxicity and pro-inflammatory conditions in phagocytic cells, as well as 
597 enhancing particle interactions with serum components. J. Nanobiotechnology 
598 2015, 13, 1–20, doi:10.1186/s12951-015-0146-9.
599 31. Fröhlich, E.; Mercuri, A.; Wu, S.; Salar-Behzadi, S. Measurements of deposition, 
600 lung surface area and lung fluid for simulation of inhaled compounds. Front. 
601 Pharmacol. 2016, 7, 1–10, doi:10.3389/fphar.2016.00181.
602 32. Caetano, L. A.; Almeida, A. J.; Gonçalves, L. M. D. Effect of experimental 
603 parameters on alginate / chitosan microparticles for BCG encapsulation. Mar. 
604 Drugs 2016, 14, 1–30, doi:10.3390/md14050090.
605 33. Fu, Y. N.; Li, Y.; Li, G.; Yang, L.; Yuan, Q.; Tao, L.; Wang, X. Adaptive 
606 Chitosan Hollow Microspheres as Efficient Drug Carrier. Biomacromolecules 
607 2017, 18, 2195–2204, doi:10.1021/acs.biomac.7b00592.
608 34. Fotakis, G.; Timbrell, J. A. In vitro cytotoxicity assays: Comparison of LDH, 
609 neutral red, MTT and protein assay in hepatoma cell lines following exposure to 
Page 25 of 37
URL: http:/mc.manuscriptcentral.com/lddi  Email:hugh.smyth@austin.utexas.edu





























































For Peer Review Only
26
610 cadmium chloride. Toxicol. Lett. 2006, 160, 171–177, 
611 doi:10.1016/j.toxlet.2005.07.001.
612 35. Wang, C.; Muttil, P.; Lu, D.; Beltran-Torres, A. A.; Garcia-Contreras, L.; 
613 Hickey, A. J. Screening for potential adjuvants administered by the pulmonary 
614 route for tuberculosis vaccines. AAPS J. 2009, 11, 139–147, doi:10.1208/s12248-
615 009-9089-0.
616 36. Braz, L.; Grenha, A.; Ferreira, D.; Rosa da Costa, A. M. A. M.; Gamazo, C.; 
617 Sarmento, B. Chitosan/sulfated locust bean gum nanoparticles: In vitro and in 
618 vivo evaluation towards an application in oral immunization. Int. J. Biol. 
619 Macromol. 2017, 96, 786–797, doi:10.1016/j.ijbiomac.2016.12.076.
620 37. Geiser, M. Update on macrophage clearance of inhaled micro- and nanoparticles. 
621 J. Aerosol Med. Pulm. Drug Deliv. 2010, 23, 207–217.
622 38. Fujihara, M.; Muroi, M.; Tanamoto, K.; Suzuki, T. Molecular mechanisms of 
623 macrophage activation and deactivation by lipopolysaccharide: Roles of the 
624 receptor complex. Pharmacol. Ther. 2003, 100, 171–194, 
625 doi:10.1016/j.pharmthera.2003.08.003.
626 39. JoAnne L. Flynn and John Chan Immunology of tuberculosis. Annu. Rev. 
627 Immunol. 2001, 19, 93–129, doi:10.4084/MJHID.2014.027.
628 40. Brodaczewska, K.; Wolaniuk, N.; Lewandowska, K.; Donskow-Łysoniewska, K.; 
629 Doligalska, M. Biodegradable chitosan decreases the immune response to 
630 Trichinella spiralis in mice. Molecules 2017, 22, 1–16, 
631 doi:10.3390/molecules22112008.
632 41. Caires, H. R.; Esteves, T.; Quelhas, P.; Barbosa, M. A.; Navarro, M.; Almeida, C. 
633 R. Macrophage interactions with polylactic acid and chitosan scaffolds lead to 
634 improved recruitment of human mesenchymal stem/stromal cells: A 
Page 26 of 37
URL: http:/mc.manuscriptcentral.com/lddi  Email:hugh.smyth@austin.utexas.edu





























































For Peer Review Only
27
635 comprehensive study with different immune cells. J. R. Soc. Interface 2016, 13, 
636 1–12, doi:10.1098/rsif.2016.0570.
637 42. Singh, B.; Maharjan, S.; Cho, K.-H.; Cui, L.; Park, I.-K.; Choi, Y.-J.; Cho, C.-S. 
638 Chitosan-based particulate systems for the delivery of mucosal vaccines against 
639 infectious diseases. Int. J. Biol. Macromol. 2018, 110, 54–64, 
640 doi:10.1016/J.IJBIOMAC.2017.10.101.
641 43. Ritz, N.; Tebruegge, M.; Connell, T. G.; Sievers, A.; Robins-Browne, R.; Curtis, 
642 N. Susceptibility of Mycobacterium bovis BCG vaccine strains to antituberculous 
643 antibiotics. Antimicrob. Agents Chemother. 2009, 53, 316–318, 
644 doi:10.1128/AAC.01302-08.
645 44. Feng, H.; Zhang, L.; Zhu, C. Genipin crosslinked ethyl cellulose-chitosan 
646 complex microspheres for anti-tuberculosis delivery. Colloids Surfaces B 
647 Biointerfaces 2013, 103, 530–537, doi:10.1016/j.colsurfb.2012.11.007.
648 45. Almeida, D.; Nuermberger, E.; Tasneen, R.; Rosenthal, I.; Tyagi, S.; Williams, 
649 K.; Peloquin, C.; Grosset, J. Paradoxical effect of isoniazid on the activity of 
650 rifampin-pyrazinamide combination in a mouse model of tuberculosis. 




Page 27 of 37
URL: http:/mc.manuscriptcentral.com/lddi  Email:hugh.smyth@austin.utexas.edu





























































For Peer Review Only
28
655 Figure captions
656 Figure 1. Scanning electron microphotographs of (a) unloaded chitosan microparticles 
657 and (b) chitosan microparticles loaded with isoniazid and rifabutin.
658
659 Figure 2. Aerodynamic deposition profiles (n = 3, mean ± SD) of isoniazid (INH) and 
660 rifabutin (RFB) in the Andersen Cascade Impactor. Drugs were associated with spray-
661 dried chitosan microparticles. Cps: capsule; Dev.: inhaler device; F: filter; IP: induction 
662 port; St: stage.
663
664 Figure 3. In vitro release of isoniazid (INH) and rifabutin (RFB) from chitosan 
665 microparticles in (a) PBS pH 7.4-Tween 80® and b) buffer at pH 5.0-Tween 80®. Mean 
666 ± SD (n = 3). *p<0.05 comparing release of the two drugs.
667    
668 Figure 4. Viability of A549 (lighter colours) and macrophage-differentiated THP-1 cells 
669 (darker colours) upon a) 3 h and b) 24 h exposure to unloaded and drug-loaded chitosan 
670 (CS) microparticles (CS/INH/RFB = 10/1/0.5, w/w). Data are expressed as a percentage 
671 of untreated cells (positive control) and indicate mean ± SEM (n = 3, six replicates per 
672 experiment at each concentration). Dashed lines represent 70% cell viability. 
673
674 Figure 5. Percentage of LDH released from A549 cells (lighter colours) and macrophage-
675 differentiated THP-1 cells (darker colours) exposed (24 h) to chitosan (CS) microparticles 
676 (1 mg/mL).  Triton X-100 and cell culture medium (CCM) were used as positive and 
677 negative controls, respectively (data from [5]). Data represent mean ± SEM (n = 3, six 
678 replicates per experiment at each concentration). *p<0.05 compared to respective CCM.
679
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680 Figure 6. Percentage (mean ± SEM; n ≥ 3) of macrophage-differentiated THP-1 cells and 
681 NR8383 phagocytosing fluorescently-labelled chitosan microparticles. Cells were 
682 exposed (2 h) to 50 and 200 µg/cm2 of microparticles. 
683
684 Figure 7. Release of a) TNF-α and b) IL-8 from macrophage-differentiated THP-1 cells 
685 induced by chitosan (raw material) and drug-loaded CS microparticles. Cell culture 
686 medium (CCM) and lipopolysaccharide (LPS) were used as negative and positive 
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1 Table 1. Aerosolisation properties (n = 3, mean ± SD) of chitosan microparticles 
2 associating isoniazid (INH) and rifabutin (RFB). The amount of drug loaded corresponds 











INH 2.7 ± 0.2 2.5 ± 0.3 4.2 ± 0.1 1.1 ± 0.2 43.6 ± 4.2
RFB 1.3 ± 0.1 1.2 ± 0.2 4.1 ± 0.2 0.5 ± 0.1 45.2 ± 3.1
4 FPD: fine particle dose; FPF: fine particle fraction; MMAD: mass median aerodynamic 
5 diameter.
6
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CCM - A549 Unloaded CS MP - A549
Drug-loaded CS MP - A549 CCM - THP-1 
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